MiR-454 promotes the progression of human non-small cell lung cancer and directly targets PTEN

Biomedicine and Pharmacotherapy

Volumn 81, Issue , 2016, Pages 79-85

  Zhu, Deng Yan ^a   Li, Xiang Nan ^a   Qi, Yu ^a   Liu, Dong Lei ^a   Yang, Yang ^a   Zhao, Jia ^a   Zhang, Chun Yang ^a   Wu, Kai ^a   Zhao, Song ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Apoptosis; MiR 454; Non small cell lung cancer; Prognosis; Proliferation; PTEN

Indexed keywords

MICRORNA; MICRORNA 454; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG; MIRN454 MICRORNA, HUMAN; PTEN PROTEIN, HUMAN;

ADULT; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION; UPREGULATION; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PTEN PHOSPHOHYDROLASE;

EID: 84962644286     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.03.029     Document Type: Article

References (26)

1. Siegel R., Naishadham D. Jemal A: cancer statistics. CA: Cancer J. Clin. 2012, 62(1):10-29.
2. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136(2):215-233.
3. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297.
4. Cech T.R., Steitz J.A. The noncoding RNA revolution-trashing old rules to forge new ones. Cell 2014, 157(1):77-94.
5. Chen C.Z. MicroRNAs as oncogenes and tumor suppressors. N. Engl. J. Med. 2005, 353(17):1768-1771.
6. Mo D., Gu B., Gong X., Wu L., Wang H., Jiang Y., Zhang B., Zhang M., Zhang Y., Xu J. miR-1290 is a potential prognostic biomarker in non-small cell lung cancer. J. Thorac. Dis. 2015, 7(9):1570-1579.
7. Dong W., Yao C., Teng X., Chai J., Yang X., Li B. MiR-140-3p suppressed cell growth and invasion by downregulating the expression of ATP8A1 in non-small cell lung cancer. Tumour Biol. 2015, PMID: 26415732. 10.1007/s13277-015-3452-9.
8. Wang R.J., Zheng Y.H., Wang P., Zhang J.Z. Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. Int. J. Clin. Exp. Pathol. 2015, 8(1):765-771.
9. Song L., Li Y., Li W., Wu S., Li Z. miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A). J. Cell. Biochem. 2014, 115(7):1234-1242.
10. Shen Z., Wu X., Wang Z., Li B., Zhu X. Effect of miR-18a overexpression on the radiosensitivity of non-small cell lung cancer. Int. J. Clin. Exp. Pathol. 2015, 8(1):643-648.
11. Yu L., Gong X., Sun L., Yao H., Lu B., Zhu L. miR-454 functions as an oncogene by inhibiting CHD5 in hepatocellular carcinoma. Oncotarget 2015, 6(36):39225-39234.
12. Liang H.L., Hu A.P., Li S.L., Xie J.P., Ma Q.Z., Liu J.Y. MiR-454 prompts cell proliferation of human colorectal cancer cells by repressing CYLD expression. Asian Pac. J. Cancer Prev. 2015, 16(6):2397-2402.
13. Sun L., Wang Q., Gao X., Shi D., Mi S., Han Q. MicroRNA-454 functions as an oncogene by regulating PTEN in uveal melanoma. FEBS Lett. 2015, 589(19 (Pt. B)):2791-2796.
14. Niu G., Li B., Sun J., Sun L. miR-454 is down-regulated in osteosarcomas and suppresses cell proliferation and invasion by directly targeting c-Met. Cell Prolif. 2015, 48(3):348-355.
15. Fang B., Zhu J., Wang Y., Geng F., Li G. MiR-454 inhibited cell proliferation of human glioblastoma cells by suppressing PDK1 expression. Biomed. Pharmacother. 2015, 75:148-152.
16. Liu L., Nie J., Chen L., Dong G., Du X., Wu X., Tang Y., Han W. The oncogenic role of microRNA-130a/301a/454 in human colorectal cancer via targeting Smad4 expression. PLoS One 2013, 8(2):e55532.
17. Liu G.F., Tang D., Li P., Wang S., Xu Y.X., Long A.H., Zhou N.L., Zhang L.L., Chen J., Xiang X.X. S-1-based combination therapy S-1 monotherapy in advanced gastric cancer: a meta-analysis. World J. Gastroenterol. 2014, 20(1):310-318.
18. Bonneau D., Longy M. Mutations of the human PTEN gene. Hum. Mutat. 2000, 16(2):109-122.
19. Hsu C.P., Kao T.Y., Chang W.L., Nieh S., Wang H.L., Chung Y.C. Clinical significance of tumor suppressor PTEN in colorectal carcinoma. Eur. J. Surg. Oncol. 2011, 37(2):140-147.
20. Stewart A.L., Mhashilkar A.M., Yang X.H., Ekmekcioglu S., Saito Y., Sieger K., Schrock R., Onishi E., Swanson X., Mumm J.B. PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol. Med. 2002, 8(8):451-461.
21. Castellino R.C., Durden D.L. Mechanisms of disease: the PI3K-Akt-PTEN signaling node-an intercept point for the control of angiogenesis in brain tumors. Nat. Clin. Pract. Neurol. 2007, 3(12):682-693.
22. Marsit C.J., Zheng S., Aldape K., Hinds P.W., Nelson H.H., Wiencke J.K., Kelsey K.T. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum. Pathol. 2005, 36(7):768-776.
23. Yun F., Jia Y., Li X., Yuan L., Sun Q., Yu H., Shi L., Yuan H. Clinicopathological significance of PTEN and PI3K/AKT signal transduction pathway in non-small cell lung cancer. Int. J. Clin. Exp. Pathol. 2013, 6(10):2112-2120.
24. Ke Z., Zhang X., Ma L., Wang L. Expression of DPC4/Smad4 in non-small-cell lung carcinoma and its relationship with angiogenesis. Neoplasma 2008, 55(4):323-329.
25. Deng L.L., Shao Y.X., Lv H.F., Deng H.B., Lv F.Z. Over-expressing CYLD augments antitumor activity of TRAIL by inhibiting the NF-kappaB survival signaling in lung cancer cells. Neoplasma 2012, 59(1):18-29.
26. Zhao R., Yan Q., Lv J., Huang H., Zheng W., Zhang B., Ma W. CHD5, a tumor suppressor that is epigenetically silenced in lung cancer. Lung Cancer 2012, 76(3):324-331.